Pancreatic Cancer Research

Clinical trialPhase 2Completed

SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer

Stereotactic Body Radiation Therapy Plus Pembrolizumab and Trametinib vs. Stereotactic Body Radiation Therapy Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection: an Open-label, Randomized, Controlled, Phase 2 Trial

NCT02704156↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Outcome unknown
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
October 2016
Expected end
December 2020
Enrollment
170 participants
Sites
1
Primary outcomes
The Median Survival Time Will be Determined.
Sponsor
Other
Results posted
2021-02-16
Last update
13 May 2022

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 10